Mabwell Bioscience Reports No Share Capital Changes in First Post-Listing Monthly Return

Bulletin Express05-07

Mabwell (Shanghai) Bioscience Co., Ltd. (abbrev. Mabwell Bioscience) has released its inaugural Monthly Return for the period ended 30 April 2026 following the company’s Main Board debut on the Hong Kong Stock Exchange (HKEX) on 28 April 2026.

Key disclosures:

• Authorised / registered share capital – H shares: 47.13 million shares, par value RMB 1.00; no change during the month. – A shares (listed on the Shanghai Stock Exchange): 399.60 million shares, par value RMB 1.00; no change. Total authorised capital remained RMB 446.73 million.

• Issued share capital and public float – H shares in issue: 47.13 million; treasury shares: nil; no movement recorded. – A shares in issue: 399.60 million; treasury shares: nil; no movement recorded. The company confirmed compliance with the HKEX minimum public-float requirement (5 % of the relevant share class).

• Corporate actions No share options, warrants, convertibles, or other equity instruments were issued, exercised, or cancelled during the reporting month.

The return was filed on 7 May 2026 by Joint Company Secretary Ms. Wang Hefei, who affirmed full compliance with applicable listing rules and regulatory obligations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108460780?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108460780","market":"hk","top_or_hot":-1,"title":"Mabwell Bioscience Reports No Share Capital Changes in First Post-Listing Monthly Return","media":"Bulletin Express","content":"<p>Mabwell (Shanghai) Bioscience Co., Ltd. (abbrev. Mabwell Bioscience) has released its inaugural Monthly Return for the period ended 30 April 2026 following the company’s Main Board debut on the Hong Kong Stock Exchange (HKEX) on 28 April 2026.</p>\n<p>Key disclosures:</p>\n<p>• Authorised / registered share capital  \n– H shares: 47.13 million shares, par value RMB 1.00; no change during the month.  \n– A shares (listed on the Shanghai Stock Exchange): 399.60 million shares, par value RMB 1.00; no change.  \nTotal authorised capital remained RMB 446.73 million.</p>\n<p>• Issued share capital and public float  \n– H shares in issue: 47.13 million; treasury shares: nil; no movement recorded.  \n– A shares in issue: 399.60 million; treasury shares: nil; no movement recorded.  \nThe company confirmed compliance with the HKEX minimum public-float requirement (5 % of the relevant share class).</p>\n<p>• Corporate actions  \nNo share options, warrants, convertibles, or other equity instruments were issued, exercised, or cancelled during the reporting month.</p>\n<p>The return was filed on 7 May 2026 by Joint Company Secretary Ms. Wang Hefei, who affirmed full compliance with applicable listing rules and regulatory obligations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mabwell Bioscience Reports No Share Capital Changes in First Post-Listing Monthly Return</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMabwell Bioscience Reports No Share Capital Changes in First Post-Listing Monthly Return\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-07 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mabwell (Shanghai) Bioscience Co., Ltd. (abbrev. Mabwell Bioscience) has released its inaugural Monthly Return for the period ended 30 April 2026 following the company’s Main Board debut on the Hong Kong Stock Exchange (HKEX) on 28 April 2026.</p>\n<p>Key disclosures:</p>\n<p>• Authorised / registered share capital  \n– H shares: 47.13 million shares, par value RMB 1.00; no change during the month.  \n– A shares (listed on the Shanghai Stock Exchange): 399.60 million shares, par value RMB 1.00; no change.  \nTotal authorised capital remained RMB 446.73 million.</p>\n<p>• Issued share capital and public float  \n– H shares in issue: 47.13 million; treasury shares: nil; no movement recorded.  \n– A shares in issue: 399.60 million; treasury shares: nil; no movement recorded.  \nThe company confirmed compliance with the HKEX minimum public-float requirement (5 % of the relevant share class).</p>\n<p>• Corporate actions  \nNo share options, warrants, convertibles, or other equity instruments were issued, exercised, or cancelled during the reporting month.</p>\n<p>The return was filed on 7 May 2026 by Joint Company Secretary Ms. Wang Hefei, who affirmed full compliance with applicable listing rules and regulatory obligations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02493","symbol_name":"迈威生物-B","start_time":0,"source_url":"","article_id":"1108460780","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108460780","pubTimestamp":1778155467,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (abbrev. Mabwell Bioscience) has released its inaugural Monthly Return for the period ended 30 April 2026 following the company’s Main Board debut on the Hong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02493":"迈威生物-B"},"translate_title":"Mabwell Bioscience在上市后首次月报表中报告股本没有变化","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02493":1},"content_text":"Mabwell (Shanghai) Bioscience Co., Ltd. (abbrev. Mabwell Bioscience) has released its inaugural Monthly Return for the period ended 30 April 2026 following the company’s Main Board debut on the Hong Kong Stock Exchange (HKEX) on 28 April 2026.\nKey disclosures:\n• Authorised / registered share capital  \n– H shares: 47.13 million shares, par value RMB 1.00; no change during the month.  \n– A shares (listed on the Shanghai Stock Exchange): 399.60 million shares, par value RMB 1.00; no change.  \nTotal authorised capital remained RMB 446.73 million.\n• Issued share capital and public float  \n– H shares in issue: 47.13 million; treasury shares: nil; no movement recorded.  \n– A shares in issue: 399.60 million; treasury shares: nil; no movement recorded.  \nThe company confirmed compliance with the HKEX minimum public-float requirement (5 % of the relevant share class).\n• Corporate actions  \nNo share options, warrants, convertibles, or other equity instruments were issued, exercised, or cancelled during the reporting month.\nThe return was filed on 7 May 2026 by Joint Company Secretary Ms. Wang Hefei, who affirmed full compliance with applicable listing rules and regulatory obligations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108460780","isCrawlerRequest":true}